Business Context and Reporting Period
This Form 8-K reports the consummation of a business combination on June 8, 2022, between Dynamics Special Purpose Corp. ("DYNS") and Senti Biosciences, Inc. ("Senti"). Following the merger, DYNS changed its name to Senti Biosciences, Inc. (the "Combined Company") and began trading on the Nasdaq Global Market under the symbol "SNTI". The Combined Company ceased to be a shell company upon closing.
Key Financial Metrics and Capital Structure
- Total Proceeds: The Combined Company received gross proceeds of approximately $140.3 million, below the expected $156.5 million due to redemptions and unfunded commitments.
- Capital Sources:
- Trust Account (net of redemptions): $84.5 million.
- PIPE Investment: $50.6 million (5,060,000 shares at $10.00/share).
- Convertible Note Exchange: $5.2 million (Bayer Healthcare LLC).
- Redemptions: DYNS stockholders redeemed 14,549,537 shares for approximately $145.5 million.
- Unfunded Commitments: $16.2 million of the original $66.8 million PIPE commitment from LifeForce Capital was not funded at closing; the company intends to enforce legal obligations.
- Shares Outstanding: 43,657,077 shares of Common Stock issued and outstanding as of the Closing Date.
- Liquidity Outlook: Management expects proceeds combined with cash on hand to fund operations into 2024.
Material Changes and Transactions
- Merger Completion: Senti became a wholly-owned subsidiary of the Combined Company. Senti stockholders received Class A Common Stock based on an exchange ratio of 0.1957.
- Contingent Consideration: Senti stockholders are eligible for up to 2,000,000 additional shares subject to share price milestones within two to three years or a change of control.
- Ownership Structure:
- Officers and directors and affiliated entities: ~42.6%.
- Former DYNS security holders: ~34.2%.
- Major Beneficial Owners include Bayer Healthcare LLC (13.5%), Dynamics Sponsor LLC (12.8%), and NEA affiliates (10.1%).
- Equity Incentives: Approved the 2022 Equity Incentive Plan (2,492,735 shares authorized) and 2022 Employee Stock Purchase Plan (592,584 shares authorized).
Guidance, Risks, and Unusual Items
- Accounting Change: The Combined Company dismissed Marcum LLP and engaged KPMG LLP as the new independent auditor. A material weakness in internal controls regarding complex financial instruments was previously identified by management.
- Lock-Up Agreements: A General Lock-Up of one year and an Extended Lock-Up of 18 months apply to certain stockholders, with an early release provision if the stock price exceeds $12.00 for 20 trading days within a 30-day period (after 150 days).
- Risk Factors: Significant risks include the ability to raise future financing, success of clinical trials and regulatory approvals, reliance on third-party manufacturers, and the impact of the COVID-19 pandemic.
- Legal Action: The company intends to pursue legal action against LifeForce Capital for the unfunded $16.2 million PIPE commitment.
Investor Verification Checklist
- Verify the status of the legal enforcement action against LifeForce Capital regarding the $16.2 million unfunded PIPE commitment.
- Review the unaudited pro forma financial statements (Exhibit 99.2) to assess the combined entity's burn rate and runway into 2024.
- Confirm the specific share price milestones required to trigger the 2,000,000 shares of contingent consideration.
- Monitor the implementation of remediation plans for the previously disclosed material weakness in internal controls over financial reporting.
- Track the vesting schedules and lock-up expiration dates for major shareholders, particularly the 18-month extended lock-up for Senti insiders.